Bilal Piperdi (@bpiperdi) header
Bilal Piperdi (@bpiperdi) profile picture

CMO, SUMMIT THERAPEUTICS, Thoracic oncologist, clinical researcher, a proud Dad. Personal account and opinions, tweets and RT are my own opinion.

Joined April 2009
Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)Photo by Bilal Piperdi (@bpiperdi)
It has been a bumpy year at personal level. As we head into #ASCO2023, thanks @GileadSciences for featuring my personal journey in Oncology. Special thanks to my Gilead team, all mentors/colleagues. We’re in this together to #endcancer #lcsm
Bilal Piperdi, Vice President of Clinical Research in Oncology, explains why he came to Gilead and how his Oncology team is helping to bring more life to people with lung cancer.

13
2,604
Bilal Piperdi retweeted
So many hot drops leading up to #ESMO26. Not to be outdone by AZUR-1, CheckMate 8HW, or any of the other incredible IO breakthroughs, Chalabi comes out with the long-term NICHE-2 follow-up. In a word? Perfect. 111 patients with locally advanced dMMR colon cancer. Just 6 weeks of neoadjuvant nivolumab/ipilimumab followed by surgery. Zero recurrences. 100% overall survival at 5 years. And remember, these weren’t all low-risk tumors. Many had high-risk stage III disease. We’re curing patients with just weeks of immunotherapy. Now, can we avoid the surgery altogether? What a time to be treating GI cancers. @TheGutOncLab @OncoAlert @Onco_Nexus sciencedirect.com/science/ar…
2
22
1
58
5,362
Bilal Piperdi retweeted
2019: AstraZeneca made a multibillion-dollar bet on a novel Asia-developed drug called T-DXd. The rest is history. 2026: AstraZeneca made a multibillion-dollar bet on a novel Asia-developed drug called Ivonescimab. History repeating itself? astrazeneca.com/media-centre…
8
22
3
153
32,789
Bilal Piperdi retweeted
Two practice-informing trials at #ESMOBreast26 carry a broader lesson for oncology: sequencing #ADCs with the same payload class — here, a TOPO1 inhibitor — may not work simply by changing the target, linker, or PK. BRE-354 from @ErikaHamilton9 @SarahCannonDocs and SATEEN from @PTarantinoMD @adawaksmd @DFCI_BreastOnc both speak to this important question. This echoes what we have seen with PD-1 after PD-1 strategies: changing the partner drug does not necessarily overcome resistance to the same core mechanism. In RCC, two randomized phase III trials showed that this approach does not generally work: TiNivo-2: shorturl.at/hP8AI CONTACT-03: shorturl.at/litTw with @montypal @motzermd @AlbigesL @BradMcG04 in @TheLancet The biology of resistance matters. Mechanism matters. Payload matters. @myESMO @ASCO @AACR @OncoAlert
3
35
2
75
7,262
Bilal Piperdi retweeted
I was curious about the most cited (non-Covid) clinical trial from the last 10 years — it's this one: 11,288 citations Pembrolizumab beat chemotherapy in PDL1–positive non–small-cell lung cancer, dislodged it as the first-line treatment (and ended up doubling median survival)
7
23
2
176
18,815
Bilal Piperdi retweeted
In 1991, US cancer death rates hit an all-time high. Advances in early detection & treatment helped bring mortality rates down, averting 4.5 million deaths. Tell your lawmakers to support cancer research funding: brnw.ch/21wXB4g #SaveResearchStopCancer #ASCOAdvocacy
1
15
19
2,647
Bilal Piperdi retweeted
The country’s highest profile Democratic politicians spent the day valorizing Dick Cheney while Democratic voters were busy electing Zohran Mamdani. Let that sink in.
98
1,696
38
11,495
148,420
60,000 white flags going up today on the National Mall, since November is Lung Cancer Awareness Month. Each flag represents two lives lost to #lungcancer. I'll share my story Wednesday at news conference, ahead of @LUNGevity's "Breathe Deep" event on Sat. Nov. 8 on the mall.
2
8
47
1,240
Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at @JAMA_current. jamanetwork.com/journals/jam…
4
33
1
92
6,787
Bilal Piperdi retweeted
Presented at #ESMO25: In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). Full ASCENT-03 phase 3 trial results: nej.md/4ncuUCV @myESMO
6
52
3
126
28,587
2 NEJM and 1 Lancet simultaneous publication
#ESMO25 Presidential symposium #2 3/4 potentially practiced changing/informing phase 3 trials conducted in China. What a change in landscape👏👏
5
336
#ESMO25 Presidential symposium #2 3/4 potentially practiced changing/informing phase 3 trials conducted in China. What a change in landscape👏👏
2
1
6
829
Finally something to improve over KN407 in 1L sq mNSCLC??? Eagerly awaiting OS results.. #ESMO25 #LCSM
1
4
421
#ESMO25 Many phase 3 trials reporting out! Need a simple way to track FDA #OncTwitter approvals? Share & bookmark this page. It's an excellent resource for busy clinicians, everyone in #cancer #drugdevelopment, & Boards prep. Below is just 1 month! #regulatory #MedTwitter 1/2
1
14
34
4,188
👉Ascent 03 now out in #NEJM 👉Sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy among patients with advanced triple-negative breast cancer who were not candidates for treatment with PD-1 or PD-L1 inhibitors. #ESMO25 #ESMO2025 #NEJM
1
5
494
Early morning walk in Barcelona for Presidential Symposium #WCLC2025
2
380
Bilal Piperdi retweeted
Congratulations @BrendonStilesMD @BalazsHalmosMD and @MontefioreNYC team on winning the @IASLC Care Team Award. It is well deserved! #WCLC25 #LCSM
1
6
2
31
3,843
Nice paper from France on Survival of Patients with Lung Adeno Dx. in 2000, 2010, and 2020 in a public hospitals. Huge impact of TKI and IO on survival! A lot more room to improve but importantly pts need access to these drugs globally!! ⁦@lcsmchat⁩ evidence.nejm.org/doi/full/1…
1
1
7
685
#GileadNews: In an open letter, Chairman and Chief Executive Officer Daniel O’Day discusses our just-approved #HIV prevention medication and its role in our fight to help end the epidemic: gilead.inc/3TuzsrI
14
22
2,292
🚨 🚨 🚨 🚨 Big news for all future J-1 physicians! Program Directors from all over the nation have received an Email from ECFMG telling them that “the U.S. Department of State has lifted the pause on new visa appointments, and J-1 physicians have been explicitly prioritized for visa interview scheduling”! Congratulations everyone! "This is more than just an update—it’s a reminder that your dedication is paying off, and the doors to your future in U.S. medicine are wide open!" #MedTwitter #IMG #j1visa
1
34
9
308
64,356
#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. gilead.inc/4e9KI6B
86
41
132
63,978